Vigabatrin | CAS#60643-86-9 | GABA Transaminase Inhibitor

MedKoo Cat#: 318979 | Name: Vigabatrin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vigabatrin, also known as gamma-vinyl-GABA, is an antiepileptic drug that inhibits the breakdown of γ-aminobutyric acid (GABA) by acting as a suicide inhibitor of GABA transaminase (GABA-T). It is a structural analog of GABA, but does not bind to GABA receptors. Vigabatrin is an irreversible suicide inhibitor of gamma-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the catabolism of GABA, which increases the level of GABA in the brain. Vigabatrin is a racemic compound, and its [S]-enantiomer is pharmacologically active.

Chemical Structure

Vigabatrin

CAS#60643-86-9

Theoretical Analysis

MedKoo Cat#: 318979

Name: Vigabatrin

CAS#: 60643-86-9

Chemical Formula: C6H11NO2

Exact Mass: 129.0790

Molecular Weight: 129.16

Elemental Analysis: C, 55.80; H, 8.58; N, 10.84; O, 24.77

Price and Availability

Size	Price	Availability
1g	USD 2,650.00	4 Weeks
2g	USD 3,950.00	4 Weeks
5g	USD 5,950.00	4 Weeks
10g	USD 7,950.00	4 Weeks
20g	USD 11,450.00	4 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

CPP109, CPP-109, CPP 109, RMI 71754, RMI71754, RMI-71754, MDL 71754, MDL-71754, MDL71754, Vigabatrin, gamma-vinyl-GABA, Sabril, Sabrilex

IUPAC/Chemical Name

4-aminohex-5-enoic acid

InChi Key

PJDFLNIOAUIZSL-UHFFFAOYSA-N

InChi Code

InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)

SMILES Code

C=CC(N)CCC(O)=O

Appearance

White to off-white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 129.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Gibson R, Klima R, Van Horn J. Liquid Medication Dosing Errors: Comparison of a Ready-to-Use Vigabatrin Solution to Reconstituted Solutions of Vigabatrin Powder for Oral Solution. Adv Ther. 2025 Feb 3. doi: 10.1007/s12325-024-03089-0. Epub ahead of print. PMID: 39899223. 2: Zheng Q, Xu SL, Guo XL, Wang CY, Ma MD, Ge JF. Effects of melatonin on the pharmacokinetics and amino acid metabolism profile of vigabatrin in rats. Toxicol Appl Pharmacol. 2025 Jan 28;496:117247. doi: 10.1016/j.taap.2025.117247. Epub ahead of print. PMID: 39884559. 3: Nielsen CU, Jakobsen S, Pedersen ML. Non-Steroidal Anti-Inflammatory Drugs Are Inhibitors of the Intestinal Proton-Coupled Amino Acid Transporter (PAT1): Ibuprofen and Diclofenac Are Non-Translocated Inhibitors. Pharmaceutics. 2025 Jan 2;17(1):49. doi: 10.3390/pharmaceutics17010049. PMID: 39861697; PMCID: PMC11768184. 4: Phitsanuwong C, Schimpf S, Yano ST. Favorable response to ketogenic diet therapy in a patient with DYNC1H1-related epilepsy. Epilepsy Behav Rep. 2024 Dec 26;29:100740. doi: 10.1016/j.ebr.2024.100740. PMID: 39834654; PMCID: PMC11743897. 5: Dubé J, Blaser S, Guerguerian AM, Hazrati LN, Yoon G. Child Neurology: Severe GMPPB-Related Congenital Muscular Dystrophy With Rapidly Progressive Encephalopathy Leading to Infantile Death. Neurology. 2025 Feb 11;104(3):e210300. doi: 10.1212/WNL.0000000000210300. Epub 2025 Jan 15. PMID: 39813629. 6: Olculu CB, Kanmaz S, Ince T, Yilmaz O, Toprak DE, Serin HM, Yilmaz S, Tekgul H. Etiology-specific subgroup analysis of initial pharmacotherapy in infantile epileptic spasm syndrome: A single-center cohort study. Eur J Paediatr Neurol. 2025 Jan 7;54:89-95. doi: 10.1016/j.ejpn.2025.01.001. Epub ahead of print. PMID: 39798199. 7: Sharma S, Dhir P, Negi S, Pal P, Suthar R, Saini A, Medhi B, Sankhyan N, Sahu JK. Short-Term Effectiveness and Tolerability of Vigabatrin Therapy in Infantile Epileptic Spasms Syndrome. Indian J Pediatr. 2025 Jan 8. doi: 10.1007/s12098-024-05332-6. Epub ahead of print. PMID: 39777716. 8: Tokatly Latzer I, Pearl PL, Roullet JB. Succinic Semialdehyde Dehydrogenase Deficiency. 2004 May 5 [updated 2025 Jan 9]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301374. 9: Laurijssen L, Jansen K, Lagae L. No single treatment modality exhibits clear superiority for infantile spasms syndrome: insights from a retrospective cohort study. Acta Neurol Belg. 2024 Dec 30. doi: 10.1007/s13760-024-02713-8. Epub ahead of print. PMID: 39738969. 10: de Sá MI, Proença F. Abnormalities in brain magnetic resonance imaging associated with vigabatrin therapy in an infant with infantile epileptic spasms syndrome. Clin Toxicol (Phila). 2024 Dec 18:1-2. doi: 10.1080/15563650.2024.2418979. Epub ahead of print. PMID: 39692122. 11: Deering L, Nelson A, Yozawitz E, Wolf S, McGoldrick P, Wu A, Basma N, Grinspan Z. A Multicenter Retrospective Observational Cohort Study of Seizure Freedom before Lennox-Gastaut Syndrome (the "Gap"). Opportunities for Prevention. medRxiv [Preprint]. 2024 Dec 5:2024.12.03.24318373. doi: 10.1101/2024.12.03.24318373. PMID: 39677451; PMCID: PMC11643183. 12: Ge W, Pang P, Zhang Z, Wan L, Yang G. Optimal lead time for treatment of infantile epileptic spasms syndrome-a secondary data analysis. Transl Pediatr. 2024 Nov 30;13(11):1994-2002. doi: 10.21037/tp-24-334. Epub 2024 Nov 26. PMID: 39649643; PMCID: PMC11621889. 13: Stevering C, Lequin M, Szczepaniak K, Sadowski K, Ishrat S, De Luca A, Leemans A, Otte W, Kwiatkowski DJ, Curatolo P, Weschke B, Riney K, Feucht M, Krsek P, Nabbout R, Jansen A, Wojdan K, Sijko K, Glowacka-Walas J, Borkowska J, Domanska-Pakiela D, Moavero R, Hertzberg C, Hulshof H, Scholl T, Petrák B, Maminak M, Aronica E, De Ridder J, Lagae L, Jozwiak S, Kotulska K, Braun K, Jansen F. Vigabatrin-associated brain magnetic resonance imaging abnormalities and clinical symptoms in infants with tuberous sclerosis complex. Epilepsia. 2024 Dec 6. doi: 10.1111/epi.18190. Epub ahead of print. PMID: 39641935. 14: Wied S, Hilgers RD, Heussen N, Kotulska K, Dirani M, Kuchenbuch M, Jozwiak S, Nabbout R. Methodological insights from the EPISTOP trial to designing clinical trials in rare diseases-A secondary analysis of a randomized clinical trial. PLoS One. 2024 Dec 3;19(12):e0312936. doi: 10.1371/journal.pone.0312936. PMID: 39625912; PMCID: PMC11614242. 15: Sathe R, Shrestha G, Terango A, Tabibzadeh D, Rajaraman RR, Nariai H, Hussain SA. Symptomatic vigabatrin-associated MRI toxicity is associated with simultaneous hormonal therapy among patients with infantile spasms. Epilepsia Open. 2024 Nov 21. doi: 10.1002/epi4.13099. Epub ahead of print. PMID: 39570186. 16: Nair A, Ewusie J, Pentz R, Whitney R, Jones K. Mean global field power is reduced in infantile epileptic spasms syndrome after response to vigabatrin. Front Neurol. 2024 Oct 25;15:1476476. doi: 10.3389/fneur.2024.1476476. PMID: 39524913; PMCID: PMC11543413. 17: Shamapari R, Nagaraj K. Upregulation of ACSL, ND75, Vha26 and sesB genes by antiepileptic drugs resulted in genotoxicity in drosophila. Toxicol Res (Camb). 2024 Nov 5;13(6):tfae180. doi: 10.1093/toxres/tfae180. PMID: 39507589; PMCID: PMC11535366. 18: Samanta D. Evolving treatment strategies for early-life seizures in Tuberous Sclerosis Complex: A review and treatment algorithm. Epilepsy Behav. 2024 Dec;161:110123. doi: 10.1016/j.yebeh.2024.110123. Epub 2024 Nov 1. PMID: 39488094. 19: Singh R, Carson RP. Vigabatrin. 2024 Oct 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32491511. 20: Nagao T, Braga JD, Chen S, Thongngam M, Chartkul M, Yanaka N, Kumrungsee T. Synergistic effects of peripheral GABA and GABA-transaminase inhibitory drugs on food intake control and weight loss in high-fat diet-induced obese mice. Front Pharmacol. 2024 Oct 2;15:1487585. doi: 10.3389/fphar.2024.1487585. PMID: 39415835; PMCID: PMC11480068.